ArticleCardiovascular and interventional radiology2026
CIRSE Standards of Practice for the Use of Non-sclerosant Liquid Embolic Agents in IR Practice.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-sclerosant liquid embolic agents are safe and effective embolics that have been used in interventional radiology for more than 50 years, in both emergency and elective scenarios. PURPOSE: This document aims to review the chemical principles and technical considerations involved, to make recommendations regarding clinical indications for the use of non-sclerosant liquid embolic agents, and to review the literature regarding outcomes and complications. CIRSE Standards of Practice documents are not intended to impose a standard of clinical patient care, but to recommend a reasonable approach to, and best practices for, procedural performance, in this instance the use of non-sclerosant liquid embolic agents.
methodsThe writing group was established by the CIRSE Standards of Practice Committee and consisted of five clinicians with internationally recognised expertise in non-sclerosant liquid embolic agents and a research assistant (P.R.). The writing group reviewed the existing literature on non-sclerosant liquid embolic agents, performing a pragmatic evidence search using PUBMED and EMBASE focussing on English-language publications, preferably from 2009 up to December 2025, and including more than ten patients. Where clear gaps were evident, older literature was searched and select references included. The final recommendations were formulated through consensus.
resultsNon-sclerosant liquid embolic agents are represented by cyanoacrylates and polymers which are safe and effective agents that can be used in a wide range of clinical scenarios, resulting in effective embolization even in patients with impaired coagulation function. Knowing their chemical properties provides understanding of their correct preparation, technical application and clinical indication. Compared to mechanical and particulate agents, non-sclerosant liquid embolic agents present a steeper learning curve, and thus, thorough training in their use is essential.
Indexed as
Identifiers
42778641What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.